Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at “competitive levels.” Says continues to prioritize investment in innovation. Says plans to increase dividend annually. Says will have “heightened focus” on cash flow generation in 2025. Expects 2025 adjusted pre-tax operating margin to increase ~300 bps. Sees 2025 effective tax rate 16.5%-17%. Says 2025 guidance excludes impact from recently announced acquisition of Intra-Cellular Therapies (ITCI). Comments taken from Q4 earnings conference call.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- JNJ Earnings: Johnson & Johnson’s Cancer Drugs and Medtech Power Q4 Revenues
- Johnson & Johnson sees 2H25 operational sales growth higher than 1H25
- Options Volatility and Implied Earnings Moves Today, January 22, 2025
- Genmab reports 2024 net sales of Darzalex $11.67B
- Johnson & Johnson reports Q4 adjusted EPS $2.04, consensus $2.02